The potential function of microRNA in chordomas

Güllüoğlu, Şükrü; Tuysuz, Emre Can; Kuşkucu, Ayşegül; Türe, Uğur; Atalay, Başar; Şahın, Fikrettin; Bayrak, Ömer Faruk

doi:10.1016/j.gene.2016.03.032

Cited by 15 publications

(27 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Published data also confirm that miR-140-3p is one of the top highly expressed miRNAs in the human brain cortex (Shao et al, 2010 ) and that it is not specific for any of the different human blood cell compounds (Leidinger et al, 2014 ). The intracellular roles exerted by miR-140-3p have been mainly investigated in human pathologies, such as cancer (Lionetti et al, 2009 ; Tan et al, 2011 ; Miles et al, 2012 ; Piepoli et al, 2012 ; Sand et al, 2012a , b ; Serrano et al, 2012 ; Bayrak et al, 2013 ; Yuan et al, 2014 ; Zou et al, 2014 ; Kong et al, 2015 ; Reddemann et al, 2015 ; Chang et al, 2016 ; Dong et al, 2016 ; Gulluoglu et al, 2016 ; Salem et al, 2016 ; Zhu et al, 2016 ), asthma (Jude et al, 2012 ; Dileepan et al, 2016 ), osteoarthritis (Rasheed et al, 2017 ), and rheumatoid arthritis (Peng J. S. et al, 2016 ). Studies on mouse and rat models have also proved its involvement in spermatogenesis (Luo et al, 2015 ) and testis differentiation (Rakoczy et al, 2013 ), chondrogenesis and growth (Pando et al, 2012 ; Waki et al, 2016 ), and sensitivity of fetal neural development to ethanol and nicotine (Balaraman et al, 2012 ).…”

Section: Discussionmentioning

confidence: 99%

Expression and Regulatory Network Analysis of miR-140-3p, a New Potential Serum Biomarker for Autism Spectrum Disorder

Cirnigliaro

Barbagallo

Gulisano

et al. 2017

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Given its prevalence and social impact, Autism Spectrum Disorder (ASD) is drawing much interest. Molecular basis of ASD is heterogeneous and only partially known. Many factors, including disorders comorbid with ASD, like TS (Tourette Syndrome), complicate ASD behavior-based diagnosis and make it vulnerable to bias. To further investigate ASD etiology and to identify potential biomarkers to support its precise diagnosis, we used TaqMan Low Density Array technology to profile serum miRNAs from ASD, TS, and TS+ASD patients, and unaffected controls (NCs). Through validation assays in 30 ASD, 24 TS, and 25 TS+ASD patients and 25 NCs, we demonstrated that miR-140-3p is upregulated in ASD vs.: NC, TS, and TS+ASD (Tukey's test, p-values = 0.03, = 0.01, < 0.0001, respectively). ΔCt values for miR-140-3p and YGTSS (Yale Global Tic Severity Scale) scores are positively correlated (Spearman r = 0.33; Benjamini-Hochberg p = 0.008) and show a linear relationship (p = 0.002). Network functional analysis showed that nodes controlled by miR-140-3p, especially CD38 and NRIP1 which are its validated targets, are involved in processes convergingly dysregulated in ASD, such as synaptic plasticity, immune response, and chromatin binding. Biomarker analysis proved that serum miR-140-3p can discriminate among: (1) ASD and NC (Area under the ROC curve, AUC: 0.70; sensitivity: 63.33%; specificity: 68%); (2) ASD and TS (AUC: 0.72; sensitivity: 66.66%; specificity: 70.83%); (3) ASD and TS+ASD (AUC: 0.78; sensitivity: 73.33%; specificity: 76%). Characterization of miR-140-3p network would contribute to further clarify ASD etiology. Serum miR-140-3p could represent a potential non-invasive biomarker for ASD, easy to test through liquid biopsy.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression and Regulatory Network Analysis of miR-140-3p, a New Potential Serum Biomarker for Autism Spectrum Disorder

Cirnigliaro

Barbagallo

Gulisano

et al. 2017

Front. Mol. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Comparison of chordoma tissue with fetal notochords reveals significant microRNA dysregulation that may precede and augment the tumorigenic effects of PD-L1 upregulation ( 55 ). MiR-574-3p, for example, is a microRNA whose expression is negatively correlated with PD-L1 expression ( 56 ). Chordomas with low miR-574-3p and high PD-L1 expression were associated with higher muscle invasion, more tumor necrosis, and poorer patient outcomes ( 55 ).…”

Section: Immune Microenvironmentmentioning

confidence: 99%

Translational Windows in Chordoma: A Target Appraisal

et al. 2020

View full text Add to dashboard Cite

Chordomas are rare tumors that are notoriously refractory to chemotherapy and radiotherapy when radical surgical resection is not achieved or upon recurrence after maximally aggressive treatment. The study of chordomas has been complicated by small patient cohorts and few available model systems due to the rarity of these tumors. Emerging next-generation sequencing technologies have broadened understanding of this disease by implicating novel pathways for possible targeted therapy. Mutations in cell-cycle regulation and chromatin remodeling genes have been identified in chordomas, but their significance remains unknown. Investigation of the immune microenvironment of these tumors suggests that checkpoint protein expression may influence prognosis, and adjuvant immunotherapy may improve patient outcome. Finally, growing evidence supports aberrant growth factor signaling as potential pathogenic mechanisms in chordoma. In this review, we characterize the impact on treatment opportunities offered by the genomic and immunologic landscape of this tumor.

show abstract

“…Chordomas are primary bone tumors that make up less than 5% of all osseous malignancies and commonly affect the spine at its vertebral body and at its two ends i.e., the skull base and the sacrum [1-3]. It is a low-grade tumor derived from the embryonic notochord [1-2,4-5].…”

Section: Introductionmentioning

confidence: 99%

“…It is a low-grade tumor derived from the embryonic notochord [1-2,4-5]. Although histologically defined to be low-grade, chordoma is locally destructive and metastatic in up to 19% of all chordoma cases, according to Bydon et al [2], and has a serious recurrence rate, which all contribute to the dismal median survival rate of six years [2-3,5]. The treatment modality of choice is an en-bloc resection [1-2].…”

Section: Introductionmentioning

confidence: 99%

“…It has been suggested that neoadjuvant radiotherapy may have a role in preventing potential hematogenous spread of the tumor during surgical manipulation [2]. However, this tumor is known to show high resistance to currently available chemoradiotherapy [1,3,5], although the effectiveness of proton beam therapy for skull base chordomas has been demonstrated [6-7]. The literature even claims that conventional chemotherapy has no role in treating this disease [3,8].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Current Understanding of MicroRNA’s Therapeutic, Diagnostic, and Prognostic Role in Chordomas: A Review of the Literature

Choi

Oskouian

Tubbs

2018

Cureus

View full text Add to dashboard Cite

Chordomas are primary low-grade bone tumors derived from the embryonic notochord that make up less than 5% of all osseous malignancies and commonly affect the spine at its vertebral body and at its two ends i.e., skull base and the sacrum. Although histologically defined to be low-grade, chordoma is locally destructive, metastatic, and has a serious recurrence rate, which all contribute to the dismal median survival rate of six years. Its locally destructive nature places the adjacent vital neurovascular structures at risk, making an en-bloc resection a challenge. This tumor is also known to show high resistance to currently available chemoradiotherapy, although the benefit of proton beam therapy for skull base chordoma has been demonstrated. There is an additional need to focus our attention on investigating the molecular biology of this chemoradiotherapy-resistant tumor to develop a more targeted therapy, which has additional diagnostic and prognostic values. In this paper, we discuss the therapeutic, diagnostic, and prognostic role of microRNAs (miRNAs) in chordomas.

show abstract

The potential function of microRNA in chordomas

Cited by 15 publications

References 28 publications

Expression and Regulatory Network Analysis of miR-140-3p, a New Potential Serum Biomarker for Autism Spectrum Disorder

Expression and Regulatory Network Analysis of miR-140-3p, a New Potential Serum Biomarker for Autism Spectrum Disorder

Translational Windows in Chordoma: A Target Appraisal

The Current Understanding of MicroRNA’s Therapeutic, Diagnostic, and Prognostic Role in Chordomas: A Review of the Literature

Contact Info

Product

Resources

About